XEN-45 Implant Effective in Uncontrolled Uveitic Glaucoma

Significant reductions seen in mean intraocular pressure, mean number of medications required

eye exam

FRIDAY, Oct. 27, 2017 (HealthDay News) -- For medically uncontrolled uveitic glaucoma, the XEN-45 implant is effective, reducing the need for further surgery, according to a study published online Oct. 20 in Clinical & Experimental Ophthalmology.

Chelvin C.A. Sng, from Moorfields Eye Hospital in London, and colleagues examined the safety and efficacy of the XEN-45 collagen implant in eyes with uveitic glaucoma in an exploratory prospective case series. Participants included 24 patients with medically uncontrolled uveitic glaucoma who were implanted with XEN-45.

The researchers found that after implantation of XEN-45, further surgery was not needed in the 20 eyes in whom conventional glaucoma surgery was thought to be inevitable. There were reductions in the mean intraocular pressure (from 30.5±9.8 to 12.2±3.1 mmHg) and in the mean number of medications required (from 3.3±0.8 to 0.4±0.9) from baseline to 12 months (both P < 0.001). Complications included hypotony in one patient, which persisted beyond two months and required surgical revision, and blebitis, which developed in one patient. The 12-month cumulative probability of survival was 79.2 percent.

"The XEN-45 implant is effective for the treatment of patients with medically uncontrolled uveitic glaucoma. Potentially sight-threatening complications, including bleb-related ocular infection and persistent hypotony, may occur," the authors write.

Two authors disclosed financial ties to Allergan, which manufactures XEN-45, and one disclosed ties to Aquesys, an Allergan affiliate.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

Updated on May 29, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ